Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence
Authors: Liu, Jiaqi L., Walker, Emily V., Paudel, Yuba Raj, Davis, Faith G., and Yuan, Yan
The incidence of BM among Canadian cancer patients is unknown. We aimed to estimate IP of BM at the time of cancer diagnosis and during the lifetime of patients with selected primary cancers. Data on BM at diagnosis from 2010–2017 was obtained from the CCR. Site-specific IPs of BM were estimated from provincial registries containing ?90% complete data on BM. The CCR IP estimates and the IP estimates from literature were applied to the total diagnosed primary cancers to estimate the number of concurrent BM and lifetime BM from 2010–2017 in Canada, respectively. The annual average number of patients with BM at diagnosis from all cancer sites was approximately 3227. The site-specific IPs of BM at diagnosis were: lung (9.42%; 95% CI: 9.16–9.68%), esophageal (1.58%; 95% CI: 1.15–2.02%), kidney/renal pelvis (1.33%; 95% CI: 1.12–1.54%), skin melanoma (0.73%; 95% CI: 0.61–0.84%), colorectal (0.22%; 95% CI: 0.18–0.26%), and breast (0.21%; 95% CI: 0.17–0.24%). Approximately 76,546 lifetime BM cases (or 5.70% of selected fifteen primary cancers sites) were estimated to have occurred from the 2010–2017 cancer patient cohort. These findings reflect results of population analyses in the US and Denmark. We recommend improved standardization of the collection of BM data within the CCR.
Please note that abstracts only appear in the language of the publication and might not have a translation.
Laetitia Amar, Michelle Le, Feras M. Ghazawi, Elham Rahme, Amanda Segal, Elena Netchiporouk, Gizelle Popradi, Linda Moreau, Osama Roshdy, Denis Sasseville, and Ivan Litvinov (2019).
Prevalence of human T cell lymphotropic virus 1 infection in Canada
Current Oncology , e3-e5
Emily V. Walker, J. Ross, Y. Yuan, T. R. Smith, and F. G. Davis (2019).
Brain cancer survival in Canada 1996-2008: Effects of sociodemographic characteristics
Current Oncology , 292-299
Y. Yuan, J. Ross, Q. Shi, and F. G. Davis (2017).
Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008
Current Oncology , 341-347
A. Blair, L. Gauvin, S. Ouédraogo, and G. Datta. (2019).
Area-level income and colorectal cancer screening among urban-dwelling Canadians: Evidence to guide future surveillance
Current Oncology , 128-137
A. C. Coronado, C. Finley, K. Badovinac, J. Han, J. Niu, and R. Rahal (2018).
Discrepancies between Canadian cancer research funding and site-specific cancer burden
Current Oncology , 338-341
Michelle Le, Feras M. Ghazawi, Akram Alakel, Elena Netchiporouk, Elham Rahme, Andrei Zubarev, Mathieu Powell, Linda Moreau, Osama Roshdy, Steven J. Glassman, Denis Sasseville, Gizelle Popradi, and Ivan V. Litvinov (2019).
Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada
Current Oncology , e473-e481
Simon F. Roy, Feras M. Ghazawi, Michelle Le, François Lagacé, Catherine F. Roy, Elham Rahme, Evgeny Savin, Andrei Zubarev, Denis Sasseville, Gizelle Popradi, and Ivan V. Litvinov (2020).
Epidemiology of adult and pediatric Burkitt Lymphoma in Canada: Sequelae of the HIV epidemic
Current Oncology , 83-89